Regulation of transcription factor E2F3a and its clinical relevance in ovarian cancer

Oncogene

Volumn 30, Issue 38, 2011, Pages 4038-4049

  Reimer, D ^a   Hubalek, M ^a   Kiefel, H ^b   Riedle, S ^b   Skvortsov, S ^a   Erdel, M ^c   Hofstetter, G ^a   Concin, N ^a   Fiegl, H ^a   Muller Holzner E ^a   Marth, C ^a   Altevogt, P ^b   Zeimet, A G ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c Krankenhaus der Barmherzigen Schwestern Linz   (Austria)

Author keywords

6p22 amplification; E2F3a; EGFR; miR 34a; ovarian cancer; prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MICRORNA; MIR 34A; TRANSCRIPTION FACTOR E2F3; TRANSCRIPTION FACTOR E2F3A; TRANSCRIPTION FACTOR E2F3B; UNCLASSIFIED DRUG;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; GENE ACTIVATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METHYLATION; MINIMAL RESIDUAL DISEASE; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN DEGRADATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; CHROMOSOMES, HUMAN, PAIR 6; DNA METHYLATION; E2F3 TRANSCRIPTION FACTOR; FEMALE; GENE AMPLIFICATION; HUMANS; MICRORNAS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; PROMOTER REGIONS, GENETIC; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 80052961221     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.119     Document Type: Article

References (24)

1. Bruch J, Schulz WA, Haussler J, Melzner I, Bruderlein S, Moller P et al. (2000). Delineation of the 6p22 amplification unit in urinary bladder carcinoma cell lines. Cancer Res 60: 4526-4530. (Pubitemid 32103635)
2. Bubendorf L, Nocito A, Moch H, Sauter G. (2001). Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol 195: 72-79.
3. Chen C, Wells AD. (2007). Comparative analysis of E2F family member oncogenic activity. PLoS ONE 2: e912.
4. Concin N, Hofstetter G, Berger A, Gehmacher A, Reimer D, Watrowski R et al. (2005). Clinical relevance of dominant-negative p73 Isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. Clin Cancer Res 11: 8372-8383. (Pubitemid 41746950)
5. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D et al. (2000). MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28: E32.
6. Feber A, Clark J, Goodwin G, Dodson AR, Smith PH, Fletcher A et al. (2004). Amplification and overexpression of E2F3 in human bladder cancer. Oncogene 23: 1627-1630. (Pubitemid 38406526)
7. Gordon AN, Finkler N, Erwards RP, Garcia AA, Crozier M, Irwin DH et al. (2005). Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 15: 785-792. (Pubitemid 41783082)
8. Koo SH, Kwon KC, Ihm CH, Jeon YM, Park JW, Sul CK. (1999). Detection of genetic alterations in bladder tumors by comparative genomic hybridization and cytogenetic analysis. Cancer Genet Cytogenet 110: 87-93. (Pubitemid 29181513)
9. Krugmann J, Tzankov A, Dirnhofer S, Fend F, Greil R, Siebert R et al. (2004). Unfavourable prognosis of patients with trisomy 18q21 detected by fluorescence in situ hybridisation in t(11;18) negative, surgically resected, gastrointestinal B cell lymphomas. J Clin Pathol 57: 360-364. (Pubitemid 38446251)
10. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H et al. (2008). Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 7: 2591-2600.
11. Markman M. (2008). Pharmaceutical management of ovarian cancer: current status. Drugs 68: 771-789. (Pubitemid 351550530)
12. Oeggerli M, Tomovska S, Schraml P, Calvano-Forte D, Schafroth S, Simon R et al. (2004). E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene 23: 5616-5623. (Pubitemid 39093039)
13. Paulson QX, McArthur MJ, Johnson DG. (2006). E2F3a stimulates proliferation, p53-independent apoptosis and carcinogenesis in a transgenic mouse model. Cell Cycle 5: 184-190. (Pubitemid 43131157)
14. Reimer D, Hubalek M, Riedle S, Skvortsov S, Erdel M, Concin N et al. (2010). E2F3a is critically involved in EGFR-directed proliferation in ovarian cancer. Cancer Res 70: 4613-4623.
15. Reimer D, Sadr S, Wiedemair A, Stadlmann S, Concin N, Hofstetter G et al. (2007). Clinical relevance of E2F family members in ovarian cancer-an evaluation in a training set of 77 patients. Clin Cancer Res 13: 144-151. (Pubitemid 46121863)
16. Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C et al. (2009). Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol 113: 21-27.
17. Simon R, Burger H, Semjonow A, Hertle L, Terpe HJ, Bocker W. (2000). Patterns of chromosomal imbalances in muscle invasive bladder cancer. Int J Oncol 17: 1025-1029.
18. Stadlmann S, Gueth U, Reiser U, Diener PA, Zeimet AG, Wight E et al. (2006). Epithelial growth factor receptor status in primary and recurrent ovarian cancer. Mod Pathol 19: 607-610.
19. Takai D, Jones PA. (2003). The CpG island searcher: a new WWW resource. In Silico Biol 3: 235-240. (Pubitemid 37493047)
20. 1-arrest. Cell Cycle 6: 1586-1593. (Pubitemid 47327945)
21. Van Cutsem E, Lang I, D'haens G, Moiseyenko J, Zaluski J, Folprecht S et al. (2008). KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol 26(Suppl): 2.
22. Veltman JA, Fridlyand J, Pejavar S, Olshen AB, Korkola JE, DeVries S et al. (2003). Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res 63: 2872-2880. (Pubitemid 36667159)
23. Welch C, Chen Y, Stallings RL. (2007). MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 26: 5017-5022. (Pubitemid 47172643)
24. Zeimet AG, Reimer D, Wolf D, Fiegl H, Concin N, Wiedemair A et al. (2009). Intratumoral interferon regulatory factor (IRF)-1 but not IRF-2 is of relevance in predicting patient outcome in ovarian cancer. Int J Cancer 124: 2353-2360.